SCYNEXIS Inc (SCYX) CEO Marco Taglietti Acquires 25,000 Shares

SCYNEXIS Inc (NASDAQ:SCYX) CEO Marco Taglietti bought 25,000 shares of SCYNEXIS stock in a transaction dated Thursday, January 10th. The shares were bought at an average price of $0.69 per share, for a total transaction of $17,250.00. Following the completion of the transaction, the chief executive officer now directly owns 480,000 shares of the company’s stock, valued at approximately $331,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Marco Taglietti also recently made the following trade(s):

  • On Tuesday, December 31st, Marco Taglietti bought 25,000 shares of SCYNEXIS stock. The shares were bought at an average price of $0.46 per share, for a total transaction of $11,500.00.
  • On Monday, December 31st, Marco Taglietti bought 25,000 shares of SCYNEXIS stock. The shares were bought at an average price of $0.46 per share, for a total transaction of $11,500.00.

Shares of SCYX stock traded up $0.06 during trading hours on Monday, reaching $0.80. 283,873 shares of the company were exchanged, compared to its average volume of 470,450. SCYNEXIS Inc has a fifty-two week low of $0.35 and a fifty-two week high of $2.15. The firm has a market capitalization of $33.82 million, a price-to-earnings ratio of -0.79 and a beta of 1.01. The company has a current ratio of 4.53, a quick ratio of 4.53 and a debt-to-equity ratio of 0.27.

SCYNEXIS (NASDAQ:SCYX) last announced its quarterly earnings data on Tuesday, November 13th. The company reported $0.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.18. SCYNEXIS had a negative net margin of 8,592.97% and a negative return on equity of 102.52%. The business had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.06 million. On average, equities research analysts forecast that SCYNEXIS Inc will post -0.51 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC acquired a new position in SCYNEXIS in the second quarter valued at approximately $190,000. BlackRock Inc. lifted its holdings in SCYNEXIS by 61.5% in the second quarter. BlackRock Inc. now owns 180,751 shares of the company’s stock valued at $296,000 after buying an additional 68,830 shares during the period. Stonepine Capital Management LLC acquired a new position in SCYNEXIS in the third quarter valued at approximately $539,000. Northern Trust Corp lifted its holdings in SCYNEXIS by 132.7% in the second quarter. Northern Trust Corp now owns 116,079 shares of the company’s stock valued at $190,000 after buying an additional 66,193 shares during the period. Finally, Private Advisor Group LLC acquired a new position in SCYNEXIS in the third quarter valued at approximately $240,000. Institutional investors and hedge funds own 41.46% of the company’s stock.

A number of equities analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of SCYNEXIS from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research report on Thursday, October 11th. HC Wainwright set a $5.00 target price on shares of SCYNEXIS and gave the stock a “buy” rating in a research report on Tuesday, October 23rd. ValuEngine upgraded shares of SCYNEXIS from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Maxim Group set a $4.00 target price on shares of SCYNEXIS and gave the stock a “buy” rating in a research report on Tuesday, November 13th. Finally, Brookline Capital Management reiterated a “buy” rating on shares of SCYNEXIS in a research report on Friday, January 4th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. SCYNEXIS currently has a consensus rating of “Buy” and a consensus price target of $4.78.

COPYRIGHT VIOLATION WARNING: “SCYNEXIS Inc (SCYX) CEO Marco Taglietti Acquires 25,000 Shares” was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.com-unik.info/2019/01/14/scynexis-inc-scyx-ceo-marco-taglietti-acquires-25000-shares.html.

About SCYNEXIS

SCYNEXIS, Inc, a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections.

Recommended Story: What is a Candlestick Chart?

Insider Buying and Selling by Quarter for SCYNEXIS (NASDAQ:SCYX)

Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit